Identifying Novel Therapies for Multiple Myeloma: Paul Richardson, MD

In the following interview, Dr. Paul Richardson, the Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute, discusses some important factors in the development of drugs to target "the queen of immunological cancers," multiple myeloma, and why this disease is difficult to cure. Recently, he led the development and clinical trials of the novel targeted cytotoxic peptide-drug, melphalan flufenamide (Pepaxto®, Oncop...

Educational Needs in the Management of Relapsed/Refractory Follicular Lymphoma

Follicular lymphoma, an indolent, difficult-to-treat B-cell malignancy, is complicated by evolving disease subtypes. Patient outcomes can be hampered by the failure of the multidisciplinary team to establish consensus on the optimal timing, schedule, and length of follicular lymphoma treatment. In addition, the rapid pace of research makes it difficult to stay abreast of the latest and most clinically relevant therapies. This educational gap in the treatment and management of follicular lymphoma...

Melphalan Flufenamide for Multiple Myeloma: Paul Richardson, MD

Melphalan flufenamide, a newly approved peptide-drug conjugate for multiple myeloma, specifically targets chemotherapy to tumor cells like a warhead on a guided missile. In the following interview, Dr. Paul Richardson, the Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute, discusses the use of melflufen (Pepaxto®, Oncopeptides AB) for multiple myeloma. Melflufen has its base in melphalan and the old technolo...

Shortfall in Knowledge Identified in Factors Used for Personalization of Urothelial Carcinoma Treatment

A shortfall in knowledge in the use of biomarkers and patient-related factors for the personalization of treatment for patients with advanced urothelial carcinoma was identified in the baseline data collected from i3 Health's continuing medical education (CME)–approved visiting faculty meeting series titled New Thinking, New Strategies in Advanced Urothelial Carcinoma, led by Arjun V. Balar, MD, Associate Professor of Medicine and Director of the Genitourinary Medical Oncology Program at NYU Lan...

Lorlatinib for Metastatic ALK-Positive Non-Small Cell Lung Cancer: Todd Bauer, MD

Recently, the FDA granted approval to lorlatinib (Lorbrena®, Pfizer, Inc.) for the treatment of patients with anaplastic lymphoma kinase (ALK)–positive non-small cell lung cancer. This subset of lung cancers defined by their chromosomal rearrangements of the ALK gene are highly sensitive to small-molecule ALK tyrosine kinase inhibitors (TKIs). Lorlatinib is a novel third-generation small-molecule ALK TKI that was designed to cross the blood-brain barrier in an effort to better treat patients who...

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.